Human Ph + leukemias are caused by the BCR-ABL1 oncogene and include CML and B-ALL. CML has a triphasic clinical course, with chronic and accelerated phases followed by a terminal blast crisis phase resembling acute leukemia, in which myeloid or lymphoid blasts fail to differentiate. Together, lymphoid blast crisis of CML and Ph + B-ALL account for 20% of adult cases and 5% of pediatric cases of acute lymphoblastic leukemia. One-half of adult and 20% of pediatric BALLs express the p210 isoform of Bcr-Abl, and the remainder express the p190 isoform 1,2 . Whereas the Abl tyrosine kinase inhibitor imatinib mesylate induces a complete hematologic response in nearly all individuals with chronic phase CML 3 , imatinib is much less effective in treating CML blast crisis and Ph + B-ALL 2 owing to acquired resistance [4] [5] [6] [7] . Drugs that target essential signaling molecules downstream of Bcr-Abl may help overcome or prevent imatinib resistance.
A R T I C L E S
Bcr-Abl-induced B-ALL, only Lyn, Hck and Fgr were prominently activated when compared with peripheral blood leukocytes from control mice (Fig. 1c) , whereas the other Src kinases were activated weakly (Blk), not activated (Lck, c-Src and Fyn; data not shown) or not expressed (Yes; data not shown). In vivo activation of Lyn and Hck was confirmed by blotting with an antibody against the phosphorylated Tyr416 homolog (Fig. 1c) . Hck was expressed at very low levels in normal peripheral blood lymphocytes but was induced by Bcr-Abl in both ENU48515 (Fig. 1b) and primary B-lymphoid leukemia cells (Fig. 1c) . These results identify Lyn, Hck and Fgr as the principal Src kinases activated by Bcr-Abl in B-lymphoid cells.
Src kinases are required for B-ALL but not CML
We next investigated whether Lyn, Hck and Fgr are involved in leukemogenesis by Bcr-Abl by using triple knockout mice deficient in all three Src kinases in separate models of CML and Ph + B-ALL. Most recipients of BCR-ABL1-transduced bone marrow from wild-type C57Bl/6 donor mice treated with 5-fluorouracil (5-FU) develop myeloproliferative disease closely resembling the chronic phase of human CML. CML-like leukemia arises from multipotential stem or progenitor cells 17 between 5 and 7 weeks after transplantation 19 . A few recipients succumb to a mixture of CML-like disease and B-ALL after 8-12 weeks (Fig. 2a) . Recipients of BCR-ABL1-transduced marrow from Lyn -/-Hck -/-Fgr -/-donor mice treated with 5-FU developed CML-like disease exclusively (Fig. 2a) , with mean peripheral blood leukocyte counts twice those of recipients of wild-type marrow (data not shown). This result indicates that these Src kinases are not required for efficient induction of CML by Bcr-Abl. There was a slight (but statistically insignificant) delay in the time to morbidity or death of mice in the Lyn -/-Hck -/-Fgr -/-cohort, which was probably due to the complete absence of B-ALL in these recipients (Fig. 2a) . Although the difference in incidence of B-ALL between the two groups was also not significant, it suggested that Src kinases might have a role in Blymphoid leukemogenesis by Bcr-Abl. Although we observed a similar defect in development of histocytic sarcoma in the recipients of BCR-ABL1-transduced Src-deficient marrow, we did not pursue this finding because this disease has no Ph + counterpart in humans.
We confirmed a requirement for Src kinases in Ph + B-lymphoblastic leukemia in a distinct mouse model of B-ALL (Fig. 2b) , where all recipients of BCR-ABL1-transduced bone marrow from wild-type donors not treated with 5-FU develop acute pre-B cell leukemia, originating from committed lymphoid progenitors, within 4-8 weeks after transplantation 17, 18 . The malignant pre-B cells express B220 and CD19 and phenotypically resemble de novo Ph + B-ALL and lymphoid blast crisis of CML. In one experiment, recipients of BCR-ABL1-transduced marrow from Lyn -/-Hck -/-Fgr -/-donors not treated with 5-FU were completely resistant to induction of B-ALL. In a second experiment that used higher titer virus stocks, most recipients (60%) remained healthy without clinical or pathological evidence of leukemia (Fig. 2b) .
Although triple Src knockout mice have developmental and proliferation defects in mature B-lymphoid cells and develop autoimmune disease with age 20 , the mice have normal early B-lymphoid development and normal bone marrow donor and recipient function. Excluding the possibility that Lyn -/-Hck -/-Fgr -/-bone marrow is deficient in B-lymphoid progenitors or less susceptible to retroviral transduction, we found no significant difference between Lyn -/-Hck -/-Fgr -/-and wild-type bone marrow with respect to the percentage of cells expressing CD19, B220, Ig heavy chain, AA4.1, Gr-1, Mac-1, c-Kit or Sca-1 (data not shown), or with respect to the efficiency of retroviral transduction of B-lymphoid progenitors (Fig. 2c) . These results indicate that one or more of these Src kinases are required for efficient induction of B-ALL by Bcr-Abl.
Several Src kinases contribute to B-cell transformation
To investigate the individual Src kinases involved in Bcr-Abl-induced Blymphoid leukemogenesis, we used an in vitro assay for transformation of bone marrow B-lymphoid progenitors by Bcr-Abl 21 , quantified by limiting dilution 22 (Fig. 2d) . These results were complemented by leukemogenesis studies in which we transplanted BCR-ABL1-transduced bone marrow from the various mutant donors, including single Lyn knockout mice, into lethally irradiated recipients (Fig. 2e) (Fig. 3a) . at higher concentrations 15 . Here, we found CGP76030 to be a weak inhibitor of Bcr-Abl in B-lymphoid cells, as we observed a significant inhibitory effect on Bcr-Abl auto-and trans-phosphorylation in BL-2 cells only at 20 µM CGP76030, whereas imatinib had a strong inhibitory effect at 0.5 µM (Fig. 3b) . These results suggest that activation of Src kinases by Bcr-Abl (which does not require Bcr-Abl kinase activity 10, 15 ) induces Src kinase autophosphorylation, and that CGP76030 selectively inhibits Src kinases over Bcr-Abl when used at concentrations less than 10 µM. This was confirmed by using the parental ENU48515 cell line, which does not express Bcr-Abl but shows a moderate level of constitutive Lyn activation. CGP76030 inhibited Lyn phosphorylation in these cells (Fig. 3c) , indicative of direct inhibition of Src kinases by this compound.
CGP inhibits B-ALL cells expressing Bcr-Abl in vitro
We also determined whether CGP76030 (CGP) could inhibit growth and survival of B-lymphoid cells expressing Bcr-Abl. CGP76030
decreased the viability (Fig. 4a ) and induced apoptosis (Fig. 4b) of BL-2 cells in a dose-dependent manner after 24 and 48 h of treatment. We observed prominent effects on cell proliferation and survival at a CGP76030 concentration of 2 µM, well below the level associated with direct inhibition of Bcr-Abl 15 . In addition to having effects on cell survival, both CGP76030 and imatinib induced apoposis of BL-2 cells, in which Bcr-Abl expression was the initial transforming event (Fig. 4c) . In contrast, ENU48515 cells do not depend on either BcrAbl or Src kinases for survival or proliferation, and hence neither drug induced apoposis of these cells (Fig. 4c) .
CGP improves survival of mice with B-ALL but not CML
As Src kinases are required for induction of B-lymphoid leukemia by Bcr-Abl (Fig. 2) , we hypothesized that they might be targets for therapy of Ph treated with CGP76030 or imatinib, alone or in combination (Fig. 5) .
Compared with a placebo, either drug alone significantly prolonged the survival of mice with BCR-ABL1-induced B-ALL, and CGP76030 in combination with imatinib was even more effective (Fig. 5a) . Prolonged survival of drug-treated mice correlated with decreased peripheral blood leukocyte counts during therapy (Fig. 5b) and less splenomegaly at necropsy (Fig. 5c) ; the combination of CGP76030 and imatinib had the greatest effect in this regard. We assessed Bcr-Abl and Src family kinase activity in primary leukemia cells isolated from pleural effusion of drug-treated B-ALL mice (Fig. 5d) . We found inhibition of Src kinase but not Bcr-Abl phosphorylation by CGP76030, whereas Bcr-Abl was inhibited by imatinib as expected. These results indicate that the in vivo concentrations of CGP76030 did not reach a level that had an inhibitory effect on Bcr-Abl and argue that the therapeutic effects of CGP76030 in Bcr-Abl-induced B-ALL are a consequence of direct inhibition of Src kinases, not of Bcr-Abl. In contrast to its therapeutic efficacy in BCR-ABL1-induced B-ALL, treatment with CGP76030 did not significantly improve the survival of mice with BCR-ABL1-induced CML-like myeloproliferative disease (Fig. 5e) , whereas treatment with imatinib resulted in a clear survival benefit, in agreement with previous findings 23 . The lack of a therapeutic effect of CGP76030 on BCR-ABL1-induced CML-like disease was also reflected by the peripheral blood leukocyte counts during therapy (Fig. 5f ) and the spleen size at necropsy (Fig. 5g) ; both parameters were decreased by imatinib treatment but unaffected by CGP76030. These results suggest that inhibition of Src kinases would be beneficial for treatment of Ph + B-ALL but not CML.
We further evaluated the effect of CGP76030 on the development of Bcr-Abl-induced B-ALL at early stages of the disease. We observed fewer circulating leukemia blasts in drug-treated mice, with the combination of CGP76030 and imatinib having the most significant effects (Fig. 6a) . The smaller spleen size in drug-treated mice with B-ALL correlated with lower numbers of leukemia blasts in the spleen (Fig. 6b) and preservation of the normal splenic follicular architecture (Fig. 6c) .
The target of CGP76030 is Src kinases, not Bcr-Abl
We determined whether CGP76030 could inhibit growth and survival of pre-B lymphoid leukemia cells expressing the Bcr-Abl T315I mutant, which is resistant to inhibition by both imatinib 4 and CGP76030 (ref. 15) . As expected, neither imatinib nor CGP76030 inhibited autophosphorylation of Bcr-Abl T315I (Fig. 7a) . CGP76030 but not imatinib decreased the number of viable pre-B leukemia cells in a dose-dependent manner after 48 h of treatment (Fig. 7b) . In parallel, CGP76030 but not imatinib induced apoptosis of pre-B cells (magenta), imatinib (blue) or both CGP76030 and imatinib (red). Peripheral blood leukocyte counts of both placebo-and drug-treated mice decrease around 18 d after transplantation owing to development of a malignant pleural effusion that is the principal cause of death (data not shown). (a) There was a significant difference in survival between placebo-treated mice (n = 14) and each drug-treated group (P = 0.014, 0.004 and <0.001 for CGP76030 (n = 13), imatinib (n = 11) and CGP76030 plus imatinib (n = 13), respectively; Mantel-Cox test). (b) The difference in leukocyte counts between placebo-treated (n = 9) and each drug-treated group on day 17 (asterisk) was statistically significant (P = 0.047, 0.007 and <0.001 for CGP76030 (n = 8), imatinib (n = 7) and CGP76030 plus imatinib (n = 9), respectively; unpaired t-test). expressing Bcr-Abl T315I at the same time point (Fig. 7c) . These results indicate that blocking Src kinases with CGP76030 has an inhibitory effect on B-lymphoid transformation that is independent of any effect on Bcr-Abl.
DISCUSSION
Imatinib mesylate induces complete hematologic and cytogenetic remissions in most newly diagnosed individuals with chronic phase CML 3 , but relatively few achieve molecular remission, suggesting that therapy with imatinib as a single agent will not be curative. In addition, imatinib is much less effective in CML blast crisis and Ph + acute lymphoblastic leukemia, due principally to development of drug resistance. [13] [14] [15] , in which transformation by Bcr-Abl does not correlate well with leukemogenesis 16 . For example, Tyr177 of Bcr-Abl is not required for transformation of 32D cells 26 but has a crucial role in CML 27 . Here, we used accurate and quantitative mouse models of chronic phase CML and Ph + acute B-lymphoblastic leukemia to investigate the role of Src family kinases in leukemogenesis by Bcr-Abl. We used mice lacking Lyn, Hck and Fgr, as these three Src kinases are the only ones expressed in early hematopoetic progenitor and myeloid cells 28 . BcrAbl induced CML-like disease in bone marrow lacking all three Src kinases. This result was complemented by treatment of leukemic mice with kinase inhibitor drugs; mice with CML-like disease responded to imatinib but not to the Src inhibitor CGP76030. We did not carry out genetic tests of the roles of other Src kinases in myeloid leukemogenesis by Bcr-Abl, but the lack of efficacy of CGP76030 (which inhibits all Src family members) in mice with Bcr-Abl-induced CML-like disease suggests that Src kinases other than Lyn, Hck and Fgr are not compensating for the lack of these three. Phosphorylation of Bcr-Abl Tyr177 is required for induction of CML-like disease 27, 29 and Hck phosphorylates this site 10 . But we found that the amount of Grb2 associated with Bcr-Abl through phosphorylated Tyr177 was not decreased in cells lacking Lyn, Hck and Fgr (Supplementary Fig. 1 online) , suggesting that Bcr-Abl itself can phosphorylate Tyr177 in addition to previously identified autophosphorylation sites 22 .
In contrast to CML, we observed a profound defect in induction of mouse B-ALL by Bcr-Abl in the absence of Lyn, Hck and Fgr. As in myeloid cells, Lyn, Hck and, to a lesser extent, Fgr are also the three main Src kinases activated by Bcr-Abl in pre-B lymphoid cells. The observation that Hck is both induced and activated by Bcr-Abl helps explain a functional role for Hck in Ph + B-ALL even though Hck is not highly expressed in nonmalignant B-lymphocytes. The development of B-ALL after considerable delay in a few recipients of BCR-ABL1-transduced Src mutant marrow when very high titer retrovirus stock was used may reflect the acquisition of additional genetic or epigenetic changes that compensate for lack of Src kinase signaling. As the disease induced in mice closely resembles both Ph + B-ALL and lymphoid blast crisis of CML, our results are suggestive of a general role for Src kinases in Ph + acute leukemia. Modeling CML myeloid blast crisis in mice requires coexpression of Bcr-Abl and an oncogenic transcription factor such as NUP98-HoxA9 (ref. 30) or AML1-EVI1 (ref. 31) , and the role of Src kinases in this disease will require further study. These genetic experiments were complemented by drug treatment studies that confirmed the therapeutic efficacy of CGP76030, a tyrosine kinase inhibitor that inhibits Src kinases more efficiently than Bcr-Abl, in mice with Bcr-Abl-induced B-ALL. The combination of CGP76030 and imatinib was significantly more effective in treating these mice than was either drug alone. Although CGP76030 can inhibit Bcr-Abl at higher concentrations 15 , we found evidence of direct inhibition of Src kinases in leukemic cells isolated from mice treated with CGP76030, whereas there was no appreciable inhibition of BcrAbl itself. In addition, we used the Bcr-Abl T315I mutant, which is resistant to both CGP76030 and imatinib 4, 15 , in a genetic strategy to verify the target of CGP76030. Whereas Src kinase inhibitor treatment of IL-3-dependent hematopoietic cells expressing the Bcr-Abl T315I mutant can either inhibit proliferation 15 or not 32 , depending on the cell type, CGP76030 had potent antiproliferative and apoptosisinducing activity on primary bone marrow-derived leukemic cells expressing Bcr-Abl T315I. These results argue that the principal target of CGP76030 in Ph + B-lymphoid leukemia is Src kinases, and not BcrAbl. Together, our preclinical studies make a specific prediction: drugs targeting Src kinases may be useful for the therapy of Ph + acute leukemia, particularly B-ALL, but will be ineffective in treating chronic phase CML. There may still be a rationale for dual kinase inhibitor therapy for individuals with chronic phase, as increased activation of Src kinases including Lyn have been observed in individuals with CML with acquired imatinib resistance 33 .
Although we used the p210 form of Bcr-Abl rather than p190, which is more common in childhood Ph + B-ALL, our results probably apply to p190-induced leukemia as well, because both forms of Bcr-Abl induce CML-like disease and B-ALL in the respective mouse models 17, 18 and both activate Src kinases in cell lines 10 . As deficiency of any one of the three individual Src kinases does not impair B-lymphoid leukemogenesis by Bcr-Abl, our results indicate that Src kinases have partially overlapping signaling functions in Ph + pre-B leukemia cells. This is reminiscent of redundant signaling by Src kinases in phagocytic cells 28 . We are currently generating mice lacking different pairs of Src kinases to investigate further the roles of the individual kinases in leukemogenesis.
These results imply that Bcr-Abl uses different signaling pathways to induce CML and Ph + B-ALL. The cells that initiate mouse CML-like disease and B-ALL are distinct 17 , and we showed previously that the Bcr-Abl SH2 domain is required for efficient induction of CML-like disease but not of B-ALL 18 . This study shows that Src kinase signaling also differs between CML and B-ALL. Several signaling pathways downstream of Src kinases in Ph + leukemia have been proposed. Hck activates Stat5 in myeloid cells expressing Bcr-Abl 11 , but Bcr-Abl can induce both CML-like disease and B-ALL in the absence of Stat5 (ref. 34) . In 32D cells expressing Bcr-Abl T315I, CGP76030 treatment inhibited Akt activation but had no effect on Stat5 activation 15 . SHP-1 interacts physically with Bcr-Abl 35 and functionally with Lyn in myeloid 36 and lymphoid 37 cells and is another possible effector of Src kinases. The identity of the important substrates of Src kinases in Blymphoid leukemia cells expressing Bcr-Abl is under investigation. The Bcr-Abl T315I mutant used in this study is an excellent reagent to identify signaling events in leukemic cells that are Src-dependent and should illuminate the pathophysiological basis of the differential requirement of Src kinases for Bcr-Abl-induced myeloid and B-lymphoid leukemia.
METHODS

Cell lines.
We isolated the pre-B cell line ENU48515 from bone marrow of a male mouse treated with the germline mutagen ENU. ENU48515 cells express AA4.1, CD19 and CD45R (B220) but not immunoglobulin (Ig) heavy chain (data not shown). We transduced the ENU48515 line with parental MSCV-IRES-GFP retrovirus without BCR-ABL1 or with MSCV-IRES-GFP virus carrying the BCR-ABL1 fusion gene 19 ABL1 isolated from a Balb/c mouse with B-ALL induced by p210 BCR-ABL1. BL-2 cells are positive for CD19, B220, CD43 and BP-1 antigens and negative for AA4.1 and Ig heavy chain (data not shown). We grew both cell lines in RPMI 1640 medium containing 10% fetal calf serum and 50 µM 2-mercaptoethanol without exogenous cytokines.
Antibodies and western-blot analysis. We purchased antibodies against phosphorylated tyrosine, c-Abl and the Src kinases Blk, Fgr, Fyn, Hck, Lck, Lyn, cSrc and Yes from Santa Cruz Biotechnology. We prepared protein lysates by lysing cells in RIPA buffer and carried out immunoprecipitation and western blotting as described previously 38 .
Bone marrow transduction and transplantation. We used the retroviral vector MSCV-IRES-eGFP 39 carrying the p210 BCR-ABL1 cDNA to make hightiter, helper-free, replication-defective ecotropic virus stock by transient transfection of 293 cells using the kat system 40 as previously described 17 . We used 4-10-week-old wild-type C57Bl/6 (Taconic Farms and The Jackson Laboratory) and homozygous Src triple knockout (Lyn -/-Hck -/-Fgr -/-) mice 28 , backcrossed 15 generations into C57Bl/6, for leukemogenesis experiments. The phenotype of the triple knockout mice is similar to that of Lyn single knockout mice; they have developmental and proliferation defects in mature B-lymphoid cells and develop autoimmune disease with age 20 . In addition, phagocytic cells from mice lacking Lyn, Hck and Fgr have functional defects in Fc gamma and LPS receptor signaling 28 . But the mice have normal early B-lymphoid development and normal bone marrow donor and recipient function, and these abnormalities do not affect leukemogenesis. We induced CML-like disease 17 and B-ALL 18 as described previously. Briefly, to model CML, we transduced bone marrow from donor mice treated with 5-FU (200 mg kg -1 ) twice with BCR-ABL1 retrovirus by cosedimentation in the presence of IL-3, IL-6 and SCF. In a C57Bl/6 background, most recipients of wild-type BCR-ABL1-transduced marrow develop myeloproliferative disease closely resembling the chronic phase of human CML 19 . To model B-ALL, we transduced bone marrow from donors not treated with 5-FU without cytokines. Under these conditions, all recipients develop fatal acute B-lymphoblastic leukemia 18 . We prepared wildtype C57Bl/6 recipient mice by 1100 cGy gamma irradiation and transplanted a dose of 0.5 × 10 6 (CML) or 1.0 × 10 6 (B-ALL) cells by tail vein injection. We analyzed diseased mice by histopathological, flow cytometric and molecular analysis as described previously 17 .
Drug treatment.
For drug treatment studies, we used Balb/c mice, as this strain develops CML-like disease with 100% incidence when donors treated with 5-FU are used 17 . We dissolved CGP76030 in 50 µl of 1 N HCl and then diluted it in distilled water to 5 mg ml -1 . We dissolved imatinib in water directly at a concentration of 10 mg ml -1 . We administered the drugs orally in a volume less than 0.5 ml by gavage twice a day at 50 mg per kg body weight per dose for CGP76030 and 100 mg per kg body weight for imatinib, beginning 2 d after bone marrow transplantation and continuing until the morbidity or death of the leukemic mice.
Note: Supplementary information is available on the Nature Genetics website.
